Semaglutide has been approved for adolescents since December 2022, and the approval is narrower than the conversation around it. It covers one product, at one age floor, studied for 68 weeks, in a trial that measured something adult trials do not measure. Reading the adolescent result as a larger version of the adult weight figure gets the direction right and the arithmetic wrong.
What is actually approved, and from what age
The Wegovy label indicates the injection for adults and pediatric patients aged 12 years and older with obesity. Wegovy tablets are not established in pediatric patients at all, and neither is the 7.2 mg weekly dose, nor any use below 12 years of age.[1] Saxenda — liraglutide 3.0 mg, a daily injection — carries a parallel indication from 12, with an extra condition: a body weight above 60 kg.[2]
Tirzepatide is the gap. The Zepbound label states plainly that safety and effectiveness have not been established in pediatric patients.[3]Mounjaro, the same molecule under the diabetes brand, was extended in December 2025 to patients 10 years and older — but for glycemic control in type 2 diabetes, which is a different indication in a different population.[4] The distinction between those two approvals is the subject of the two-approvals article.
So the approved route for a 14-year-old is an FDA-approved branded injection, prescribed and monitored inside pediatric care, alongside the diet and activity program the label names as part of the indication. The 2023 American Academy of Pediatrics guideline places pharmacotherapy there, as an adjunct offered to adolescents aged 12 and over with obesity together with health behavior and lifestyle treatment, not instead of it.[5] A compounded vial bought on a cash subscription is not that route: compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, efficacy or quality before they are dispensed, which the compounding article sets out in full.
What STEP TEENS measured
STEP TEENS randomized 201 pubertal patients aged 12 and older with a BMI at or above the 95th percentile for age and sex, two to one, to semaglutide 2.4 mg weekly or placebo for 68 weeks after a 12-week lifestyle run-in. Mean age was 15, mean baseline body weight 108 kg.[6] The primary endpoint was the percentage change in BMI, and it fell 16.1% on semaglutide against a 0.6% rise on placebo — an estimated difference of 16.7 percentage points (95% CI, −20.3 to −13.2).[6]
A 5% weight reduction was reached by 73% of the semaglutide group against 18% on placebo, an odds ratio of 14.0 (95% CI, 6.3 to 31.0).[6]A secondary analysis asked a question adults are never asked: whether treatment moved a patient out of the obesity category at all. It did for 44.9% on semaglutide against 12.1% on placebo, an odds ratio of 22.7 (95% CI, 7.6 to 67.9). Class III obesity fell from 37.3% to 13.6% under treatment, and rose in the placebo group.[7]
The comparison with adults runs through two different rulers
Here is the number that complicates the headline. In the same trial, percentage change in body weight was −14.7% on semaglutide and +2.7% on placebo, against a BMI change of +0.6% in that same placebo arm.[1] Those adolescents gained nearly three percent of their body weight over 68 weeks and their BMI barely moved, because they also grew. BMI has height in its denominator, and in a 15-year-old the denominator is not fixed.
That is why an adolescent percentage and an adult percentage do not stack cleanly. The adult STEP 1 extension reports a mean 17.3% loss of body weight at 68 weeks.[8] The adolescent headline is a 16.1% fall in a ratio. A model-informed analysis pooling STEP TEENS with roughly 3,100 adult participants found semaglutide exposure in adolescents comparable to adults, with body weight the main covariate — which is the evidence that the effect really is of similar size, and it took a pharmacokinetic model rather than a shared endpoint to establish it.[9] That same analysis is what supported the 1.7 mg adolescent maintenance dose, with no dedicated adolescent trial behind it.[9]
Pooling shrinks the number, and changes the ranking
Across 18 randomized trials covering 1,402 children and adolescents, the pooled effects are far smaller than the STEP TEENS figure: body weight −3.02 kg (95% CI, −4.98 to −1.06), BMI −1.45 kg/m² (95% CI, −2.40 to −0.49), HbA1c −0.44% (95% CI, −0.68 to −0.21).[10] Median treatment duration in that pool was 0.51 years, and it mixes agents and indications. The pooled number is not a correction to STEP TEENS; it is what the whole field averages to once the weaker drugs and shorter trials are in the denominator.
A 2026 network meta-analysis of 41 trials and 3,923 participants then produces the reversal. Semaglutide gave the largest continuous reduction in BMI relative to the 95th percentile, −20.40% (95% CI, −24.22 to −16.58), ahead of phentermine–topiramate at −18.35%. Counted as responders, the order flips: phentermine–topiramate produced 554 and 734 additional patients per 1,000 person-years reaching 5% and 10% reductions, against 500 and 399 for semaglutide, and the authors name phentermine–topiramate the optimal adjunct.[11] Same trials, two instruments, opposite conclusion about which drug to choose.
Growth and puberty: what was recorded and what was not
STEP TEENS enrolled pubertal patients and ran for 68 weeks. It did not report height velocity or pubertal staging as outcomes, and neither did SCALE Teens.[6][12] A 2026 review of incretin therapy during adolescence states the position directly: critical knowledge gaps remain on the long-term effects of these drugs on growth, pubertal development, cognition, neural reward processing and lifelong energy-balance regulation.[13] There is no adolescent bone density dataset in this class either.
Sixty-eight weeks is the longest randomized exposure on record in this age group. Peak bone mass accrues over roughly a decade. Nothing published covers that window, and anyone describing adolescent safety as established beyond the trial horizon is describing something that has not been measured. The lean-tissue question that sits underneath it is adult-only evidence, set out in the body-composition article.
What the label does record is a divergence from adults in the side-effect mix. Adverse reactions in pediatric patients were generally similar, with greater incidences of cholelithiasis, cholecystitis, hypotension, rash and urticaria than in adults on the same drug.[1] Gallstones appeared in 4% of the semaglutide arm in STEP TEENS and in none of the placebo arm.[6] On the Saxenda side, the pediatric trial recorded one case of pancreatitis, more self-monitored hypoglycemia than placebo, and resting heart-rate increases of 3 to 7 beats per minute.[2]
Stopping was measured in adolescents, once
SCALE Teens randomized 251 adolescents to liraglutide 3.0 mg or placebo for 56 weeks, then followed them for 26 weeks off treatment. On drug, the BMI standard deviation score fell by an estimated 0.22 more than placebo (95% CI, −0.37 to −0.08).[12] After withdrawal it rose more in the group that had been treated, an estimated difference of 0.15 (95% CI, 0.07 to 0.23).[12] Adverse events led 10.4% of the liraglutide group to discontinue, against none on placebo.
STEP TEENS has no published off-treatment extension, so the semaglutide rebound evidence is adult: in the STEP 1 extension, participants regained 11.6 of the 17.3 percentage points they had lost by week 120.[8]What that pattern means for a course that starts at 14 is covered for adults in the withdrawal article and has not been studied in anyone younger.
Outside a trial, the numbers are smaller
A single-center observational study followed 51 patients aged 8 to 18 on liraglutide for a mean of 9.7 months. A 5% BMI reduction was reached by 37.3% and a 10% reduction by 13.7%. Only 39.2% were still on treatment, while 33.3% discontinued, mostly for gastrointestinal reasons.[14]Patients who continued lost 6.7% against 0.7% among those who stopped (p = 0.03).
That is a different drug from semaglutide and a small cohort, but it measures the thing a 68-week supervised trial cannot: whether an adolescent stays on a daily injection without the trial structure around them. The cost side of staying on one is in the coverage article.
What none of this decides
Whether a particular adolescent should be prescribed one of these drugs is a decision for a pediatric clinician who has the growth chart, the comorbidities and the family in front of them. The published evidence supports a real and large effect on BMI over about a year and a half, in one molecule, at one dose, under supervision — and says nothing at all about the decade after.
The commercial reading follows from that. Adult cash telehealth plans, including those compared on the semaglutide board, are built for adults buying compounded product without an FDA-approved indication behind it. The approved adolescent pathway runs through a branded prescription and a pediatric practice, and those are not the same transaction. How this site establishes a claim before publishing it is described in the methodology.